WHERE THE BRIGHTEST MINDS in health and IT meet.
February 19-23, 2017
The rapid expansion of biologics and the recent introduction of biosimilars to the US healthcare market represents an exciting public health opportunity. While offering an opportunity to lower costs, it also signifies a potential opportunity to re-evaluate the role that EHRs, CPOE and pharmacy systems play in capturing appropriate information for improved traceability adverse event reporting and outcomes research. As more biosimilars are approved and enter the market, it will become increasingly challenging and important to accurately identify and distinguish the source of the adverse events (AEs) from a biosimilar, its reference biologic and other biosimilars. EHRs, CPOE and Pharmacy systems are an integral component of this process. This essential conversation will bring stakeholders involved in the writing/ordering, capturing, dispensing and administering of biologics and biosimilars to discuss and potentially reassess current information captured through the systems to ensure tracking and traceability of patient adverse events.